However, improved energy levels may help some people become more active. Any weight change is indirect and related to increased activity, not fat loss caused by the injection
doi: 10.1085/jgp.200409082
By the end of the 30 days, the participants saw a reduction in total fat mass, while experiencing an increase in muscle mass
WynneKParkAJSmallCJPattersonMEllisSMMurphyKGet al
By activating telomerase and enhancing immune surveillance, the peptide can slow tumor growth and promote cellular apoptosis in malignant cells Anisimov et al., Neuroendocrinology Letters , 2003
Sources Wegovy is now accessible to eligible Medicare beneficiaries living with obesity through Medicare GLP-1 Bridge Novo Nordisk July 1, 2026 Medicare to cover GLP-1 drugs for weight loss starting July 1